Cover Image
市場調查報告書

受體型蛋白酪氨酸激酶ERBB4:開發中產品分析

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363580
出版日期 內容資訊 英文 113 Pages
訂單完成後即時交付
價格
Back to Top
受體型蛋白酪氨酸激酶ERBB4:開發中產品分析 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H2 2017
出版日期: 2017年08月08日 內容資訊: 英文 113 Pages
簡介

本報告提供糖原合成酵素激酶β (GSK3β)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

糖原合成酵素激酶β (GSK3β)的概要

治療藥的開發

糖原合成酵素激酶β (GSK3β):開發中的產品 - 各開發階段

糖原合成酵素激酶β (GSK3β):開發中的產品 - 各治療範圍

糖原合成酵素激酶β (GSK3β):開發中的產品 - 各適應症

糖原合成酵素激酶β (GSK3β):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

糖原合成酵素激酶β (GSK3β):企業開發中的產品

糖原合成酵素激酶β (GSK3β):大學/機關開發中的產品

糖原合成酵素激酶β (GSK3β):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

糖原合成酵素激酶β (GSK3β)的治療藥的開發企業

  • AMO Pharma Limited
  • Angelini Group
  • Celon Pharma Sp. z o.o.
  • DiaMedica Inc.
  • HitGen LTD
  • Jeil Pharmaceutical Co., Ltd.
  • 田邊三菱製藥
  • Neurim Pharmaceuticals Ltd

藥物簡介

糖原合成酵素激酶β (GSK3β):暫停中的計劃

糖原合成酵素激酶β (GSK3β):開發中止的產品

糖原合成酵素激酶β (GSK3β):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0957TDB

Summary:

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-4 is an enzyme that in humans is encoded by the ERBB4 gene. Receptor tyrosine-protein kinase erbB-4 is a receptor tyrosine kinase that is a member of the epidermal growth factor receptor subfamily. it plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. It is required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation, normal development of the embryonic central nervous system, especially for normal neural crest cell migration, normal axon guidance, mammary gland differentiation, induction of milk proteins and lactation. It acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1, 4, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System and Gastrointestinal which include indications Gastric Cancer, Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Colorectal Cancer, Esophageal Cancer, Solid Tumor, Breast Cancer, Glioblastoma Multiforme (GBM), Bile Duct Cancer (Cholangiocarcinoma), Low-Grade Glioma, Lung Adenocarcinoma, Metastatic Brain Tumor, Pancreatic Cancer, Recurrent Glioblastoma Multiforme (GBM), Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Biliary Tumor, Brain Cancer, Cervical Cancer, Chordoma, Chronic Heart Failure, Crohn's Disease (Regional Enteritis), Endometrial Cancer, Ependymoma, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, High-Grade Glioma, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Lung Cancer, Meningioma, Metastatic Biliary Tract Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Necrotizing Enterocolitis, Neuroblastoma, Oligodendroglioma, Ovarian Cancer, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Rhabdomyosarcoma, Skin Cancer, Systolic Heart Failure, Ulcerative Colitis, Urinary Tract Cancer and Uterine Cancer.

Furthermore, this report also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1)
  • The report reviews Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Overview
    • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    • Aslan Pharmaceuticals Pte Ltd
    • Boehringer Ingelheim GmbH
    • GamaMabs Pharma SA
    • Hanmi Pharmaceuticals Co Ltd
    • Jiangsu Kanion Pharmaceutical Co Ltd
    • Minerva Neurosciences Inc
    • Pfizer Inc
    • Puma Biotechnology Inc
    • Shanghai Fosun Pharmaceutical (Group) Co Ltd
    • XuanZhu Pharma Co Ltd
    • Zensun (Shanghai) Sci & Tech Co Ltd
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Drug Profiles
    • afatinib dimaleate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dacomitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FCN-411 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MIN-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize HER4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • neratinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neucardin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NRG-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-113 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PB-357 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pirotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • poziotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sirotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKLB-1206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • varlitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • yinlitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Z-650 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Dormant Products
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Discontinued Products
  • Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 21, 2017: NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting
      • Jul 20, 2017: NERLYNX tablets for HER2+ Breast Cancer in the Extended Adjuvant Setting
      • Jul 19, 2017: Onco360 Chosen For NERLYNX Limited Distribution Pharmacy Network
      • Jul 17, 2017: U.S. Food and Drug Administration Approves Puma's NERLYNX (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
      • Jul 10, 2017: Lung Cancer: VeriStrat Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy
      • Jul 06, 2017: Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial
      • Jun 29, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Global Pivotal Treetopp Study For Varlitinib In Biliary Tract Cancer
      • Jun 12, 2017: Aslan Pharmaceuticals Announces MTD For Varlitinib In Combination With Chemotherapies Commonly Used In First Line Gastric Cancer
      • Jun 05, 2017: Research suggests possible new treatment for EGFR-positive lung cancer
      • Jun 03, 2017: Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting
      • Jun 02, 2017: Aslan Pharmaceuticals Announces Publication of New Varlitinib Data in Metastatic Solid Tumors at ASCO
      • Jun 01, 2017: Aslan Pharmaceuticals Receives Clinical Trial Authorisation To Initiate Pivotal Study Of Varlitinib In Gastric Cancer
      • May 30, 2017: NICE Terminates Technology Appraisal for Afatinib in Advanced Squamous NSCLC After Platinum-based Chemotherapy
      • May 22, 2017: Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting
      • May 18, 2017: New Data On Varlitinib Published At 2017 Annual Meeting Of American Society Of Cancer Oncology
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017
  • Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Pipeline by GamaMabs Pharma SA, H2 2017
  • Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
  • Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017
  • Pipeline by Minerva Neurosciences Inc, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Pipeline by Puma Biotechnology Inc, H2 2017
  • Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd, H2 2017
  • Pipeline by XuanZhu Pharma Co Ltd, H2 2017
  • Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top